These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31298686)

  • 1. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
    Drexel H; Rosano GMC; Lewis BS; Huber K; Vonbank A; Dopheide JF; Mader A; Niessner A; Savarese G; Wassmann S; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):97-103. PubMed ID: 31298686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?
    Sun Y; Hasegawa K; Drexel H
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):278. PubMed ID: 38697932
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of Purified Anthocyanins in Improving Cardiometabolic Risk Factors in Chinese Men and Women with Prediabetes or Early Untreated Diabetes-A Randomized Controlled Trial.
    Yang L; Ling W; Yang Y; Chen Y; Tian Z; Du Z; Chen J; Xie Y; Liu Z; Yang L
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 28994705
    [No Abstract]   [Full Text] [Related]  

  • 4. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 5. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.
    Figliuzzi I; Presta V; Citoni B; Miceli F; Simonelli F; Battistoni A; Coluccia R; Ferrucci A; Volpe M; Tocci G
    Clin Cardiol; 2018 Jun; 41(6):788-796. PubMed ID: 29604091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials.
    Pirro M; Mannarino MR; Bianconi V; Simental-Mendía LE; Bagaglia F; Mannarino E; Sahebkar A
    Pharmacol Res; 2016 Aug; 110():76-88. PubMed ID: 27157250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
    Sepúlveda C; Palomo I; Fuentes E
    Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question?
    Psaty BM; Fleming TR
    Am J Hypertens; 2019 Sep; 32(10):927-929. PubMed ID: 31175821
    [No Abstract]   [Full Text] [Related]  

  • 13. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia.
    Chou WL
    Pharmacol Res; 2021 Aug; 170():105693. PubMed ID: 34048925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucose and LDL lowering: the need for intensive therapy.
    Del Prato S
    Curr Vasc Pharmacol; 2012 Nov; 10(6):687-9. PubMed ID: 23259554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of vascular risk factors in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).
    Meschia JF; Voeks JH; Leimgruber PP; Mantese VA; Timaran CH; Chiu D; Demaerschalk BM; Howard VJ; Hughes SE; Longbottom M; Howard AG; Brott TG
    J Am Heart Assoc; 2014 Nov; 3(6):e001180. PubMed ID: 25428209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiometabolic University 2017: Meeting Review and Presentation Summaries.
    Rengarajan R
    Rev Cardiovasc Med; 2018 Mar; 19(1):27-31. PubMed ID: 31032600
    [No Abstract]   [Full Text] [Related]  

  • 19. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
    van Stee MF; de Graaf AA; Groen AK
    Cardiovasc Diabetol; 2018 Jun; 17(1):94. PubMed ID: 29960584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical controversies in lipid management.
    Tziomalos K
    Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.